Tarke Alison, Sidney John, Kidd Conner K, Dan Jennifer M, Ramirez Sydney I, Yu Esther Dawen, Mateus Jose, da Silva Antunes Ricardo, Moore Erin, Rubiro Paul, Methot Nils, Phillips Elizabeth, Mallal Simon, Frazier April, Rawlings Stephen A, Greenbaum Jason A, Peters Bjoern, Smith Davey M, Crotty Shane, Weiskopf Daniela, Grifoni Alba, Sette Alessandro
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Department of Internal Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa 16132, Italy.
Cell Rep Med. 2021 Feb 16;2(2):100204. doi: 10.1016/j.xcrm.2021.100204. Epub 2021 Jan 26.
T cells are involved in control of SARS-CoV-2 infection. To establish the patterns of immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific CD4 and CD8 T cells, we study epitope-specific T cell responses of 99 convalescent coronavirus disease 2019 (COVID-19) cases. The SARS-CoV-2 proteome is probed using 1,925 peptides spanning the entire genome, ensuring an unbiased coverage of human leukocyte antigen (HLA) alleles for class II responses. For HLA class I, we study an additional 5,600 predicted binding epitopes for 28 prominent HLA class I alleles, accounting for wide global coverage. We identify several hundred HLA-restricted SARS-CoV-2-derived epitopes. Distinct patterns of immunodominance are observed, which differ for CD4 T cells, CD8 T cells, and antibodies. The class I and class II epitopes are combined into epitope megapools to facilitate identification and quantification of SARS-CoV-2-specific CD4 and CD8 T cells.
T细胞参与了对严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染的控制。为了确定不同SARS-CoV-2抗原的免疫显性模式并精确测量病毒特异性CD4和CD8 T细胞,我们研究了99例2019冠状病毒病(COVID-19)康复患者的表位特异性T细胞反应。使用覆盖整个基因组的1925种肽对SARS-CoV-2蛋白质组进行探测,以确保对II类反应的人类白细胞抗原(HLA)等位基因进行无偏差覆盖。对于HLA I类,我们研究了另外5600个针对28个主要HLA I类等位基因的预测结合表位,以实现广泛的全球覆盖。我们鉴定出数百个HLA限制性SARS-CoV-2衍生表位。观察到不同的免疫显性模式,CD4 T细胞、CD8 T细胞和抗体的模式有所不同。将I类和II类表位组合成表位大池,以促进SARS-CoV-2特异性CD4和CD8 T细胞的鉴定和定量。